DVS Sciences receives $14.6 million in series A financing

DVS Sciences — a Univ of Toronto spin-off — has secured $14.6 million in series A financing, the largest venture-based series A equity financing in the life sciences and medical technology fields in recent years. DVS has developed CyTOF, an analytical instrument that dramatically speeds up the analysis of biomarkers. It recently analyzed 34 biomarkers simultaneously in single leukemia cells at a rate of 1,000 cells/second with absolute signal quantification. DVS Sciences received early seed financing from the Ontario Institute for Cancer Research and was supported by its Entrepreneur in Residence program. The financing was provided by Mohr Davidow Ventures, Pfizer Venture Investments and Roche Finance Ltd. DVS will establish manufacturing facilities in Ontario....